[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391: 1301-1314.
[2] Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell, 2019, 179: 561-577.e22.
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, DOI: 10.3322/caac.21660
[4] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析.中华肿瘤杂志,2019, 01: 19-28.
[5] KUDO M, MATSUI O, IZUMI N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology, 2014, 87(Suppl 1): 22-31.
[6] Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer, 2015, 4: 188-199.
[7] He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer, 2017, 36: 704-711.
[8] Raymond E, Faivre S, Chaney S, et al. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther, 2002, 1: 227-235.
[9] Ueda M, Sai K, Sonoda T, et al. Complications arising from transfemoral, percutaneous implantation of an indwelling port-catheter system for hepatic infusion chemotherapy: case series of the management and salvage of the system. Int J Surg Case Rep, 2019, 65: 78-82.
[10] Iwasa S, Ikeda M, Okusaka T, et al. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol, 2011, 41: 770-775.
[11] Ishikawa T, Kubota T, Abe S, et al. Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival. Ann Oncol, 2014, 25: 1379-1384.
[12] Ueshima K, Kudo M, Takita M, et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology, 2010, 78: 148-153.
[13] Monden M, Sakon M, Sakata Y, et al. 5-fluorouracil arterial infusion+interferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study. Hepatol Res, 2012, 42: 150-165.
[14] Hu JG, Bao Q, Cao G, et al. Hepatic arterial Infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc Intervent Radiol, 2020, 43: 996-1005.
[15] He MK, Li QJ, Zou RH, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol, 2019, 5: 953-960.
[16] Shi M, Li Q, He M, et al. 981O Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): a randomised phase III trial. Annals of Oncology, 2020, 31(Supl.4):S688-S688.
[17] Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut, 2018, 67: 395-396.
[18] 陈嵩,吴志强,庄文权,等.经肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗治疗肝细胞癌合并门静脉癌栓15例近期临床疗效评价. 介入放射学杂志, 2019, 28: 328-333.
[19] Rathore R, Safran H, Soares G, et al. Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study. Am J Clin Oncol, 2010, 33: 43-46.
[20] Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol, 2018, 69: 60-69.
[21] Chen SG, Zhang KZ, Liu WF, et al. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate?and advanced stage hepatocellular carcinoma: a phase II, single-arm, prospective study. Eur J Cancer, 2020, 134: 90-98.
[22] Liu M, Shi JY, Mou T, et al. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol, 2020, 35: 1277-1287.
[23] Shimose S, Iwamoto H, Tanaka M, et al. Alternating lenvatinib and trans-arterial therapy prolongs overall survival in patients with inter-mediate stage hepato cellular carcinoma: a propensity score matching study. Cancers (Basel), 2021, 13: 160.
[24] Kodama K, Kawaoka T, Aikata H, et al. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. J Gastroenterol Hepatol, 2018, 33: 1780-1786.
[25] Guo WB, Gao J, Zhuang WQ, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: a propensity score-matching cohort study. JGH Open, 2020, 4: 477-483.
[26] Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer, 2005, 103: 2419-2426.
[27] Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis. Oncology, 2018, 94: 215-222.
[28] Nouso K, Matsumoto E, Kobayashi Y, et al. Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies. J Gastroenterol Hepatol, 2008, 23: 453-458.
[29] Oyama A, Nouso K, Yoshimura K, et al. Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma. Hepatol Res, 2021, DOI: 10.1111/hepr.13633
[30] Moran A, Ramos L, Picado O, et al. Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis. J Surg Oncol, 2019, 119: 455-463.
[31] Lee BH, Lee DS, Cho CW, et al. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol, 2019, 17: 143.
[32] Yamamoto S, Onishi H, Takaki A, et al. The early decline of α-fetoprotein and des-γ-carboxy prothrombin predicts the response of hepatic arterial infusion chemotherapy in hepatocellular carcinoma patients. Gastrointest Tumors, 2020, 7: 83-92.
[33] Sung PS, Choi MH, Yang H, et al. Diffusion-weighted magnetic resonance imaging in hepatocellular carcinoma as a predictor of a response to cisplatin-based hepatic arterial infusion chemotherapy. Front Oncol, 2020, 10: 600233.
[34] Imamine R, Shibata T, Shinozuka K, et al. Complications in hepatic arterial infusion chemotherapy: retrospective comparison of catheter tip placement in the right/left hepatic artery vs. the gastroduodenal artery. Surg Today, 2017, 47: 851-858. |
